+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial



Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial



Annals of Internal Medicine 128(12 Pt 1): 975-981



Background: Hepatic complications are a major cause of illness and death after bone marrow transplantation. Objective: To confirm the results of a pilot study that indicated that ursodiol prophylaxis could reduce the incidence of veno-occlusive disease of the liver. Design: Randomized, double-blind, placebo-controlled study. Sefting: Tertiary care teaching hospital. Patients: 67 consecutive patients undergoing transplantation with allogeneic bone marrow (donated by a relative) in whom busulfan plus cyclophosphamide was used as the preparative regimen and cyclosporine plus methotrexate was used to prevent graft-versus-host disease. Intervention: Before the preparative regimen was started, patients were randomly assigned to receive ursodiol, 300 mg twice daily (or 300 mg in the morning and 600 mg in the evening if body weight was > 90 kg), or placebo. Measurements: Patients were prospectively evaluated for the clinical diagnosis of veno-occlusive disease, the occurrence of acute graft-versus-host disease, and survival. Results: The incidence of veno-occlusive disease was 40% (13 of 32 patients) in placebo recipients and 15% (5 of 34 patients) in ursodiol recipients (P = 0.03). Assignment to placebo was the only pretransplantation characteristic that predicted the development of veno-occlusive disease. The most significant predictor of 100-day mortality was the diagnosis of veno-occlusive disease. The difference in actuarial risk for hematologic relapse in patients with chronic myelogenous leukemia and nonhepatic toxicities between the two groups was not statistically significant (13% in the ursodiol group and 20% in the placebo group; P > 0.2). Conclusion: Ursodiol prophylaxis seemed to decrease the incidence of hepatic complications after allogeneic bone marrow transplantation in patients who received a preparative regimen with busulfan plus cyclophosphamide.

(PDF emailed within 1 workday: $29.90)

Accession: 009702104

Download citation: RISBibTeXText

PMID: 9625683


Related references

Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplantation 15(6): 949-954, 1995

Human recombinant GM-CSF in allogeneic bone marrow transplantation for leukaemia: double-blind placebo controlled trial. Bone Marrow Transplantation 7 Suppl 2: 85-86, 1991

Human recombinant gm csf in allogeneic bone marrow transplantation for leukemia double blind placebo controlled trial. Lancet 336(8728): 1417-1420, 1990

Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Annals of Internal Medicine 118(3): 179-184, 1993

Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 100(10): 3479-3482, 2002

Long-term safety of GM-CSF (molgramostim) administration after allogeneic bone marrow transplantation for hematologic malignancies: five-year follow-up of a double-blind randomized placebo-controlled study. Leukemia & Lymphoma 24(3-4): 301-307, 1997

A randomized double-blind trial of prophylactic ursodeoxycholic acid vs placebo to prevent veno-occlusive disease of the liver in patients undergoing allogeneic bone marrow transplantation. Blood 84(10 SUPPL 1): 250A, 1994

Recombinant human non-glycosylated granulocyte-macrophage colony-stimulating factor in allogeneic bone marrow transplantation: double-blind placebo-controlled phase III clinical trial. Japanese Journal of Clinical Oncology 24(4): 205-211, 1994

COMPARE CPM-RMI Trial: Intramyocardial Transplantation of Autologous Bone Marrow-Derived CD133+ Cells and MNCs during CABG in Patients with Recent MI: A Phase II/III, Multicenter, Placebo-Controlled, Randomized, Double-Blind Clinical Trial. Cell Journal 20(2): 267-277, 2018

The use of recombinant gm csf after allogeneic bone marrow transplantation a randomized double blind trial. Bone Marrow Transplantation 5(SUPPL 2): 40, 1990

Randomized, double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor in breast cancer patients following autologous bone marrow transplantation. Blood 90(10 SUPPL 1 PART 1): 580A, Nov 15, 1997

Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 119(10): 984-991, 1993

IV immuneglobulin prophylaxis in allogeneic sibling stem cell transplant patients A randomized, dose-effect, placebo-controlled, double-blind, multicenter trial. Blood 98(11 Part 1): 779a-780a, November 16, 2001

Design and rationale of a randomized, double-blind, placebo-controlled phase III study for autologous bone marrow cell transplantation in critical limb ischemia: the BONe Marrow Outcomes Trial in Critical Limb Ischemia (BONMOT-CLI). Vasa. Zeitschrift für Gefasskrankheiten 37(4): 319-325, 2008

Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Annals of Internal Medicine 139(1): 8-18, 2003